Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.

The new microbiologica - 1 Apr 2004

Sarmati L, Montano M, Dori L, Buonomini A R, D'Ettorre G, Vullo V, Andreoni M

Abstract excerpt

The aim of this study was to evaluate outcome after a genotype guided change of therapy in 18 patients failing HAART. Patients were divided into two groups according to the response to therapy: immune responders (12 patients with immune recovery defined as having more than 100 CD4 cells compared to baseline value), and 6 failing patients (without immune recovery). At month 12 after genotype change of therapy a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Viral Load

Share to Viremia

Share to Virus Replication

Source

Identifiers

PMID: 15646070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.PMID 15646070Read ↗

Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.Semantic proximity Read ↗

Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch.Semantic proximity Read ↗

High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.Semantic proximity Read ↗

Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPheRex Study.Semantic proximity Read ↗

Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3.Semantic proximity Read ↗

Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.Semantic proximity Read ↗

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.Semantic proximity Read ↗

Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.Semantic proximity Read ↗

Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production.Semantic proximity Read ↗

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.Semantic proximity Read ↗

A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).Semantic proximity Read ↗

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.